Assessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Share Price Weakness And Pipeline Progress

Recent performance context for Supernus Pharmaceuticals

Without a single headline event driving attention today, Supernus Pharmaceuticals (SUPN) is on some investors’ radars after a mixed stretch. The stock is down about 3% over the past month and 14% over the past 3 months.

See our latest analysis for Supernus Pharmaceuticals.

At a share price of US$48.21, Supernus Pharmaceuticals has seen short term share price weakness, with the 90 day share price return down 14.4%, while the 1 year total shareholder return of 47.9% points to stronger longer term momentum and shifting expectations around growth and risk.

If you are looking beyond a single biopharmaceutical stock, this may be a good moment to see what else is moving in healthcare related AI, including 34 healthcare AI stocks

So with Supernus shares easing back in recent months but still showing strong multi year total returns and an estimated intrinsic discount, is the stock quietly undervalued here, or is the market already pricing in future growth?

Most Popular Narrative: 23.3% Undervalued

Supernus Pharmaceuticals’ most followed narrative pegs fair value at US$62.83 per share, well above the last close of US$48.21. This sets up a valuation story built on growth, margins and product breadth.

Deep pipeline progress, along with advancements in late-stage candidates like SPN-820 (major depressive disorder) and SPN-443 (next-gen ADHD/CNS disorders), supports future earnings and revenue growth through innovative, differentiated therapies with potentially larger addressable markets.

Read the complete narrative.

Want to see what underpins this valuation gap? The narrative leans heavily on accelerating earnings, rising margins and a richer product mix. Curious how those pieces fit together into the fair value math?

Result: Fair Value of US$62.83 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, there are still real pressure points to watch, including heavy dependence on Qelbree and GOCOVRI, as well as the risk that ONAPGO supply plans slip or underdeliver.

Find out about the key risks to this Supernus Pharmaceuticals narrative.

Next Steps

With mixed sentiment around both risks and rewards, this is a good time to quickly review the details and decide where you stand using 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that fit your goals even better. Use the Simply Wall St Screener to keep ideas flowing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com